Austedo Generic Name Deutetrabenazine DrugBank Accession Number DB12161 Background Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor …

Deutetrabenazine, sold under the brand name Austedo, is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

Mar 9, 2025 · Austedo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions …

Mechanism of Action Deutetrabenazine exerts its action after getting metabolized to α-dihydrotetrabenazine (HTBZ) and β-HTBZ, its major metabolites that reversibly inhibit VMAT2, which …

Deutetrabenazine (Austedo) can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of deutetrabenazine …

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AUSTEDO XR or AUSTEDO safely and effectively. See full prescribing information for …

Jul 17, 2024 · Deutetrabenazine, also known by its brand name Austedo, is a medication primarily used to treat involuntary movements (chorea) associated with Huntington's disease and tardive …

Feb 28, 2025 · AUSTEDO XR extended-release tablets and AUSTEDO tablets are formulated with deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration.

Jun 26, 2024 · How does Austedo work (mechanism of action)? Austedo works to lower neurotransmitter levels, which are chemicals in the body that are communicated between cells.